Overall, our results suggest that SHK-loaded nanodrugs can effectively target key molecular pathways in CRC and provide a promising strategy for colorectal cancer treatment with advantages such as improved drug stability, tumor-specific targeting, and reduced systemic toxicity. Here, SHPK is linked to colorectal carcinoma.